A proposta da transferência das unidades Endpoint Clinical e Fortrea Patient Access agiliza ainda mais o foco estratégico da Fortrea como uma organização de pesquisa sob contrato
Read more »
A proposta da transferência das unidades Endpoint Clinical e Fortrea Patient Access agiliza ainda mais o foco estratégico da Fortrea como uma organização de pesquisa sob contrato
Read more »
Vorgeschlagene Veräußerung der Geschäftsbereiche Endpoint Clinical und Fortrea Patient Access optimiert Fortreas strategische Ausrichtung als reines Auftragsforschungsinstitut
Read more »
Le projet de cession des activités Endpoint Clinical et Fortrea Patient Access permet à Fortrea de se recentrer sur son cœur de métier stratégique d’organisme de [...] Read more »
Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea’s strategic focus as a pure–play contract research organization
Read more »
LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Read more »
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial [...] Read more »
WALTHAM, Massachusetts, 07 mars 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la [...] Read more »
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias voltadas [...] Read more »
WALTHAM, Massachusetts, March 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, ein weltweit tätiges Biopharmazieunternehmen, dessen Ziel eine führende Rolle in der Entwicklung und Kommerzialisierung von [...] Read more »
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology–directed [...] Read more »